Jwan A. Naser MBBS, Hossam H. Ibrahim MBBCh, Serena Rahme MD, Kartik Andi MD, Christopher G. Scott MS, Austin M. Kennedy BS, Jeremy J. Thaden MD, Mackram F. Eleid MD, Robert P. Frantz MD, Maurice Enriquez-Sarano MD, William R. Miranda MD, Garvan C. Kane MD, PhD, Sorin V. Pislaru MD, PhD
{"title":"Prognostic Value of Tricuspid Regurgitation in Pulmonary Hypertension and Among the Different WHO Groups","authors":"Jwan A. Naser MBBS, Hossam H. Ibrahim MBBCh, Serena Rahme MD, Kartik Andi MD, Christopher G. Scott MS, Austin M. Kennedy BS, Jeremy J. Thaden MD, Mackram F. Eleid MD, Robert P. Frantz MD, Maurice Enriquez-Sarano MD, William R. Miranda MD, Garvan C. Kane MD, PhD, Sorin V. Pislaru MD, PhD","doi":"10.1016/j.jcmg.2026.04.016","DOIUrl":"10.1016/j.jcmg.2026.04.016","url":null,"abstract":"<div><h3>Background</h3><div>Secondary tricuspid regurgitation (STR) is frequently observed in patients with pulmonary hypertension (PH). Whether it independently confers mortality risk beyond the associated right ventricular (RV) dysfunction remains unknown.</div></div><div><h3>Objectives</h3><div>The aim of this study was to evaluate the prognostic significance of STR in patients with PH other than related to left-sided valve disease or reduced ejection fraction and across the individual WHO (World Health Organization) groups of PH.</div></div><div><h3>Methods</h3><div>Patients with RV systolic pressures ≥50 mm Hg on echocardiography between 2010 and 2023 and measured RV free wall longitudinal strain were identified retrospectively. Primary tricuspid valve disease, reduced left ventricular ejection fraction, significant left-sided valve disease, congenital heart disease, decompensated cirrhosis, malignancy, and dialysis were exclusion criteria. PH was classified according to the WHO group classification. Patients were followed for all-cause mortality.</div></div><div><h3>Results</h3><div>Of 1,318 patients (mean age 67 years, 61% women, 29% with moderate or greater STR, median RV free wall longitudinal strain 19%), WHO groups 1, 2, 3, and 4 PH were present in 33%, 11%, 32%, and 12%, respectively. Patients with moderate or greater STR were more symptomatic and congested and had worse RV function and pulmonary pressures. Over a median 1.5 years (Q1-Q3: 0.3-4.6 years), 454 patients died. Moderate or severe STR was associated with mortality independent of various RV function measures or RV–pulmonary arterial coupling. This remained true across the individual WHO groups of PH.</div></div><div><h3>Conclusions</h3><div>Moderate or severe STR conferred mortality risk in patients with PH without left-sided valve disease or reduced left ventricular ejection fraction, beyond what can be explained by the associated RV dysfunction or impaired RV–pulmonary arterial coupling. Whether STR may represent an additional therapeutic target in certain subgroups with PH requires future investigation.</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"19 8","pages":"Pages 907-919"},"PeriodicalIF":19.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148211343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Angeli MD, PhD, Matteo Armillotta MD, Alberto Foà MD, PhD, Damiano Fedele MD, Vincenzo Russo MD, Rachele Bonfiglioli MD, Chiara Baldovini MD, Cristina Mosconi MD, Pasquale Paolisso MD, PhD, Sara Amicone MD, Lisa Canton MD, Marta Belmonte MD, Gianluca Folesani MD, Giacomo Murana MD, Sofia Martin-Suarez MD, Luciano Potena MD, PhD, Stefano Fanti MD, Davide Pacini MD, Luigi Lovato MD, Luca Bergamaschi MD, Carmine Pizzi MD
{"title":"Diagnostic Accuracy of an Integrated Multimodality Imaging Approach in Patients With Cardiac Masses","authors":"Francesco Angeli MD, PhD, Matteo Armillotta MD, Alberto Foà MD, PhD, Damiano Fedele MD, Vincenzo Russo MD, Rachele Bonfiglioli MD, Chiara Baldovini MD, Cristina Mosconi MD, Pasquale Paolisso MD, PhD, Sara Amicone MD, Lisa Canton MD, Marta Belmonte MD, Gianluca Folesani MD, Giacomo Murana MD, Sofia Martin-Suarez MD, Luciano Potena MD, PhD, Stefano Fanti MD, Davide Pacini MD, Luigi Lovato MD, Luca Bergamaschi MD, Carmine Pizzi MD","doi":"10.1016/j.jcmg.2026.03.014","DOIUrl":"10.1016/j.jcmg.2026.03.014","url":null,"abstract":"<div><h3>Background</h3><div>Multimodality imaging plays a central role in the evaluation of cardiac masses (CMs), yet the comparative performance of integrated imaging strategies including cardiac magnetic resonance (CMR), cardiac computed tomography (CCT), and <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography (PET) remains incompletely defined.</div></div><div><h3>Objectives</h3><div>This study sought to compare the diagnostic accuracy of multiparametric scores derived from echocardiography, CMR, CCT, and <sup>18</sup>F-FDG PET, individually and in combination, for identifying malignant CMs using histology as the reference standard.</div></div><div><h3>Methods</h3><div>In this prospective study, patients with suspected CMs underwent echocardiography, CCT, CMR, and <sup>18</sup>F-FDG PET within 2 months of first medical contact. Final diagnosis was established by histology or radiological resolution after anticoagulation therapy for thrombi. Diagnostic performance was assessed using receiver-operating characteristic curves, and the areas under the curve (AUCs) were compared with the DeLong test, applying Bonferroni correction for multiple comparisons. CART (Classification And Regression Tree) analysis assessed the incremental value of PET following CMR or CCT.</div></div><div><h3>Results</h3><div>Among 142 patients, 54% had malignant CMs. Echocardiography showed the lowest diagnostic accuracy (AUC: 0.77). CMR demonstrated the highest standalone performance (AUC: 0.94), outperforming CCT and <sup>18</sup>F-FDG PET (both AUCs: 0.85). The combination of CMR and <sup>18</sup>F-FDG PET was associated with high diagnostic accuracy (AUC: 0.97; positive predictive value 95.1%; negative predictive value 100%), whereas CCT combined with <sup>18</sup>F-FDG PET achieved an AUC of 0.92. The addition of PET after CMR or CCT was associated with improved diagnostic classification in selected cases, as supported by CART analysis.</div></div><div><h3>Conclusions</h3><div>CMR provides the highest standalone accuracy for malignancy detection. In inconclusive cases, adding <sup>18</sup>F-FDG PET further improves diagnostic performance, while CCT combined with <sup>18</sup>F-FDG PET represents a reliable alternative.</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"19 8","pages":"Pages 923-936"},"PeriodicalIF":19.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John J. Lopez MD, Rick H.J.A. Volleberg MD, Doosup Shin MD, Emily Janak MD, Akiko Maehara MD, Fernando Alfonso MD, Gary S. Mintz MD, Francesco Burzotta MD, Sengottuvelu Gunasekaran MD, Robert McNutt PhD, Jana Buccola MS, Hong Nie PhD, Robert McGreevy, Amir Darki MD, MSc, Ulf Landmesser, Gregg W. Stone MD, Ziad A. Ali MD, DPhil, ILUMIEN IV Investigators
{"title":"OCT-Defined Plaque Morphology and Clinical Outcomes After Percutaneous Coronary Intervention","authors":"John J. Lopez MD, Rick H.J.A. Volleberg MD, Doosup Shin MD, Emily Janak MD, Akiko Maehara MD, Fernando Alfonso MD, Gary S. Mintz MD, Francesco Burzotta MD, Sengottuvelu Gunasekaran MD, Robert McNutt PhD, Jana Buccola MS, Hong Nie PhD, Robert McGreevy, Amir Darki MD, MSc, Ulf Landmesser, Gregg W. Stone MD, Ziad A. Ali MD, DPhil, ILUMIEN IV Investigators","doi":"10.1016/j.jcmg.2026.05.015","DOIUrl":"10.1016/j.jcmg.2026.05.015","url":null,"abstract":"<div><h3>Background</h3><div>Optical coherence tomography (OCT) can differentiate plaque morphology (fibrous, lipidic, and calcified) within atherosclerotic lesions. The prognostic impact of predominant OCT plaque type after percutaneous coronary intervention (PCI) is unclear.</div></div><div><h3>Objectives</h3><div>The aim of this study was to investigate clinical outcomes after PCI based on the preprocedural predominant plaque morphology from the OCT cohort of the ILUMIEN IV trial.</div></div><div><h3>Methods</h3><div>Subjects assigned to OCT guidance (n = 1,233) underwent core laboratory analysis to determine predominant lesion plaque morphology: lipidic (maximum arc ≥180° or thin-cap fibroatheroma), calcific (maximum arc ≥180°), or fibrotic. The primary endpoint was target-vessel failure (TVF), a composite of cardiac death, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization (ID-TVR).</div></div><div><h3>Results</h3><div>PCI of a single de novo lesion was performed in 926 patients. By OCT, the plaque was predominantly lipidic, calcific, and fibrotic in 309 (33%), 252 (27%), and 365 (39%) cases, respectively. After multivariable adjustment, patients undergoing PCI of a predominantly calcific lesion had increased rates of TVF (10.7% vs 4.0%; adjusted HR: 2.20 [95% CI: 1.12-4.33]; <em>P</em> = 0.02) driven by greater ID-TVR (8.2% vs 3.1%; adjusted HR: 2.31 [95% CI: 1.08-4.96]; <em>P</em> = 0.03) compared with PCI of a fibrotic lesion. Event rates in patients undergoing PCI of a predominantly lipidic lesion were intermediate (TVF 5.6% and ID-TVR 4.0%).</div></div><div><h3>Conclusions</h3><div>Based on preprocedural OCT, PCI of calcific and fibrotic plaques was associated with the highest and lowest 2-year rates of TVF and ID-TVR, respectively, with lipidic plaques being of intermediate risk. This is the first report from a large-scale clinical trial that demonstrates the prognostic utility of baseline OCT plaque morphology on post-PCI outcomes. (ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention [PCI]; <span><span>NCT03507777</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"19 8","pages":"Pages 970-980"},"PeriodicalIF":19.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148660851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Riyad Yazan Kherallah MD, Nathaniel R. Smilowitz MD, Ali Ahmad MD, Huzaifa Ahmad MD, Shuang Li MS, Karen Chiswell PhD, Mahmoud Al Rifai MD, Vijay Nambi MD, Jennifer Rymer MD, Hani Jneid MD
{"title":"Trends in the Evaluation of Acute Chest Pain","authors":"Riyad Yazan Kherallah MD, Nathaniel R. Smilowitz MD, Ali Ahmad MD, Huzaifa Ahmad MD, Shuang Li MS, Karen Chiswell PhD, Mahmoud Al Rifai MD, Vijay Nambi MD, Jennifer Rymer MD, Hani Jneid MD","doi":"10.1016/j.jcmg.2026.03.012","DOIUrl":"10.1016/j.jcmg.2026.03.012","url":null,"abstract":"","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"19 8","pages":"Pages 1013-1015"},"PeriodicalIF":19.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147874254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicola Ciocca MD, Delia Brändle BMed, Lars Riederer BMed, Kady Fischer PhD, Jonathan Schütze MD, Andreas Wahl MD, Giulin Tanner MD, Dominik P. Guensch MD, Kiril Stoyanov MD, Chrysoula Garefa MD, Maryam Pavlicek-Bahlo MD, Moritz Hundertmark MD, DPhil, Isaac Shiri PhD, Benedikt Bernhard MD, Raymond Y. Kwong MD, MPH, Christoph Gräni MD, PhD
{"title":"Atrial Function by Long Axis Shortening Enhances Risk Stratification Beyond Traditional CMR Markers in Possible Myocarditis","authors":"Nicola Ciocca MD, Delia Brändle BMed, Lars Riederer BMed, Kady Fischer PhD, Jonathan Schütze MD, Andreas Wahl MD, Giulin Tanner MD, Dominik P. Guensch MD, Kiril Stoyanov MD, Chrysoula Garefa MD, Maryam Pavlicek-Bahlo MD, Moritz Hundertmark MD, DPhil, Isaac Shiri PhD, Benedikt Bernhard MD, Raymond Y. Kwong MD, MPH, Christoph Gräni MD, PhD","doi":"10.1016/j.jcmg.2026.04.006","DOIUrl":"10.1016/j.jcmg.2026.04.006","url":null,"abstract":"<div><h3>Background</h3><div>Left ventricular ejection fraction (LVEF) and cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) are established risk markers for patients with myocarditis. Whether atrial functional impairment may occur in this clinical setting, and whether this finding offers incremental prognostic value, remains unknown.</div></div><div><h3>Objectives</h3><div>The authors sought to evaluate the association of left atrial (LA) and right atrial (RA) long axis shortening (LAS) assessed by CMR with major cardiovascular adverse events (MACE) in patients with possible myocarditis.</div></div><div><h3>Methods</h3><div>Patients meeting 2025 European Society of Cardiology criteria for “possible myocarditis” undergoing CMR at 2 tertiary centers, without coronary artery disease or alternative diagnosis, were included. LAS was associated with a composite of first MACE (heart failure hospitalization, sustained ventricular tachycardia, recurrent myocarditis, and all-cause mortality).</div></div><div><h3>Results</h3><div>A total of 787 patients (age 48 ± 16 years, 36% female) were included. LA-LAS was 21.5% ± 10.1%, and RA-LAS 29.5% ± 12.1%. After a median follow-up of 3.5 years (Q1-Q3: 1.8-6.5 years), 17.5% experienced a MACE. In the univariate analysis, both LA-LAS (per 5% decrease) (HR: 1.37; 95% CI: 1.23-1.52; <em>P</em> < 0.001) and RA-LAS (HR: 1.27; 95% CI: 1.19-1.37; <em>P</em> < 0.001), were associated with MACE. In multivariable models, LA-LAS below the median (22%) (HR: 2.17; 95% CI: 1.33-3.57; <em>P</em> = 0.002) and RA-LAS below the median (29%) (HR: 1.75; 95% CI: 1.12-2.70; <em>P</em> = 0.012) both independently predicted MACE. Adding LA-LAS and RA-LAS to the baseline model (clinical variables, left ventricular end-diastolic volume, LVEF, and LGE) resulted in improved risk stratification for MACE (chi-square increase by 11.3; <em>P</em> < 0.001; C-index from 0.72 to 0.75).</div></div><div><h3>Conclusions</h3><div>Atrial dysfunction can be present in possible myocarditis and atrial LAS was independently and incrementally associated with outcomes beyond traditional CMR markers and may refine future risk stratification in this clinical setting. (CMR Features in Patients With Suspected Myocarditis [CMRMyo]; <span><span>NCT03470571</span><svg><path></path></svg></span>; Inflammatory Cardiomyopathy Bern Registry [FlamBER]; <span><span>NCT04774549</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"19 8","pages":"Pages 940-950"},"PeriodicalIF":19.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}